BETHESDA, MdFour institutions have received SPORE (Specialized
Program of Research Excellence) grants from the NCI for ovarian
cancer research. The grants, totaling $5.85 million for the first
year, went to:
The University of Texas M.D. An-derson Cancer Center, to pursue
chemo-prevention, antiangiogenesis, and novel treatments for the disease.
Fred Hutchinson Cancer Research Center, to establish the Pacific
Ovarian Cancer Research Consortium, whose efforts will include
studies of genes responsible for resistance to chemotherapy and the
development of a nucleic acid vaccine for prevention of the disease.
Fox Chase Cancer Center, to develop an interdisciplinary ovarian
cancer program focused on carcinogenesis, prevention, and treatment
of the cancer.
The University of Alabama at Birmingham, for the development of a new
genetically engineered monoclonal antibody therapy, targeted
immunotherapy, and research to find markers of disease progression
that can be used as targets for chemoprevention.